A5084759728- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Colorectal Cancer Surgical Treatments
- HER2/EGFR in Cancer Research
- Neutropenia and Cancer Infections
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Histiocytic Disorders and Treatments
- Gastric Cancer Management and Outcomes
- Angiogenesis and VEGF in Cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer survivorship and care
- Global Cancer Incidence and Screening
- Chemotherapy-related skin toxicity
- Multiple Myeloma Research and Treatments
- Pharmaceutical Economics and Policy
- Endometrial and Cervical Cancer Treatments
Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics
2024
Iowa Oncology Research Association
2010-2023
National Cancer Institute
2003-2022
Hematology Oncology Associates
2010-2021
WinnMed
2013
NSABP Foundation
2013
Mayo Clinic
2005-2012
Mercy Health
2012
Mayo Clinic in Florida
2012
North Central Cancer Treatment Group
2012
Abstract BACKGROUND: There is increasing evidence that paclitaxel and carboplatin are clinically active in the treatment of metastatic melanoma (MM). ABI‐007 an albumin‐bound formulation has demonstrated single‐agent activity against melanoma. METHODS: A parallel phase II trial was conducted patients with unresectable stage IV who were either chemotherapy naive (CN) or previously treated (PT). The regimen consisted (100 mg/m 2 ) area under curve (AUC2) administered on days 1, 8, 15 every 28...
Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of taxane and platinum-based chemotherapy. Several studies have supported the potential benefit glutathione for prevention platinum-induced CIPN. The current trial was designed to determine whether would prevent CIPN as result carboplatin/paclitaxel therapy.In total, 185 patients who received treatment with paclitaxel carboplatin were accrued between December 4, 2009 19, 2011. Patients randomized receive either...
The Oncotype DX colon cancer assay is a clinically validated predictor of recurrence risk in stage II patients. This prospective study evaluated the impact score (RS) results on physician recommendations regarding adjuvant chemotherapy T3, mismatch repair-proficient (MMR-P) Patients and Methods. Stage IIA patients were enrolled 17 centers. Patient tumor specimens assessed by RS test (quantitative reverse transcription-polymerase chain reaction) repair (immunohistochemistry). For each...
e15169 Background: In metastatic colorectal cancer with deficient DNA mismatch repair (dMMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival compared to lack of benefit for cancers proficient MMR. an ongoing phase III randomized trial, we will determine if the addition anti-PD-L1 antibody, atezolizumab (Genentech), adjuvant FOLFOX can improve patient disease-free (DFS) vs alone in patients stage colon dMMR. By blocking PD-1/PD-L1...
Gemcitabine, oxaliplatin and 5-fluorouracil (5-FU) are active in biliary tract cancer have a potentially synergistic mode of action non-overlapping toxicity. The objective these trials was to determine response, survival toxicity separately patients with bile duct (BDC) gallbladder (GBC) treated gemcitabine/oxaliplatin/5-FU chemotherapy. Eligible histologically proven, advanced or metastatic BDC (n=37) GBC (n=35) were gemcitabine (900 mg m−2 over 30 min), (65 m−2) 5-FU (1500 24 h) on days 1...
PURPOSE NCI-MATCH is a precision medicine trial using genomic testing to allocate patients with advanced malignancies targeted treatment subprotocols. This report combines two subprotocols evaluating trametinib, MEK1/2 inhibitor, in Neurofibromatosis 1 ( NF1[S1] or GNA11/Q [S2]) altered tumors. METHODS Eligible had tumors deleterious inactivating NF1 mutations by the customized Oncomine AmpliSeq panel. Prior MEK inhibitor was excluded. Glioblastomas (GBMs) were permitted, including...
TPS3630 Background: In metastatic colorectal cancer with deficient DNA mismatch repair (MMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival compared to lack of benefit for proficient MMR tumors (Le, M, et al, NEJM 2016). We propose a phase III randomized trial determine if the addition anti-PD-L1 antibody, atezolizumab (Genentech™), adjuvant FOLFOX can improve patient disease-free (DFS) vs alone in patients stage colon cancers dMMR...
Prior economic analysis that compared the 12-gene assay to published patterns of care predicted would improve outcomes while lowering medical costs for stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer patients. This study assessed validity those findings with real-world adjuvant chemotherapy (aCT) recommendations from US third-party payer perspective.
Enthusiasm for precision oncology may obscure the psychosocial and ethical considerations associated with implementation of tumor genetic sequencing. Patients advanced cancer undergoing tumor-only sequencing in National Cancer Institute Molecular Analysis Therapy Choice (MATCH) trial were randomized to a web-based education intervention or usual care. The primary outcomes knowledge, anxiety, depression, cancer-specific distress collected at baseline (T0), posteducation (T1) after results...
The standard therapies of surgery, radiotherapy, and hormonal manipulations often fail to control metastatic prostate cancer (PC). Docetaxel thalidomide may have activity in refractory PC. We highlight the potential pulmonary toxicity when docetaxel is combined with thalidomide. reviewed three examples at National Cancer Institute (NCI) summarized published literature regarding toxicity. has following four main presentations: (1) symptomatic effusions; (2) dyspnea on exertion without any...
4026 Background: Patients (pts) with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma commonly receive neoadjuvant chemoradiotherapy (chemo-RT). Despite this approach the rate of recurrence remains high. Given difficulties postoperative therapy, efficacy extended therapy was assessed. Methods: Eligibility criteria included T3-4,N0 – T any ,N(+) disease amenable to radiation and surgery. Pts were randomized either arm A (docetaxel 60 mg/m 2 day 1 , oxaliplatin...
Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis, and no standard first-line therapy currently exists. Here, we report the results phase II study utilizing combination gemcitabine irinotecan as therapy. Treatment was with 1000 mg/m(2) 75 weekly times four on six week cycle (Cohort I). Due to excessive toxicity, dose schedule were modified follows: 750 given three II). The endpoint confirmed response rate (CR + PR). Secondary endpoints consisted adverse events based...
How do oncologists choose therapy for the elderly? Oncologists assigned patients aged 65 years or older with incurable non-small cell lung cancer to: (a) carboplatin (AUC = 2) + paclitaxel 50 mg/m2 days 1, 8, 15 (28-day cycle × 4) followed by gefitinib; (b) gefitinib 250 mg/day. With (a), 12 of 34 were progression-free at 6 months; median time to progression was 3.9 months. (b), same occurred in 11 28 latter being 4.9 The most common reason conventional chemotherapy oncologists’ opinion that...
Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study
3640 Background: Prior economic analysis of a 12-gene assay (Oncotype DX), compared with patterns care reported in the NCCN database patients stage II, T3, DNA mismatch repair proficient (MMR-P) colon cancer, predicted that would save medical costs and improve patient well-being (Hornberger et al. Value Health 2012). This study assessed validity those findings actual adjuvant chemotherapy (aCT) recommendations. Methods: Outcomes were estimated for MMR-P cancer using Markov model. A 141 from...
453 Background: A 12-gene assay (Oncotype DX Colon Cancer) has been clinically validated as a predictor of recurrence risk in stage 2 colon cancer patients following surgery. We conducted the first prospective study to characterize impact Recurrence Score results on medical oncologists’ recommendations regarding adjuvant chemotherapy T3, Mismatch Repair-proficient (MMR-P) patients. Methods: Consecutive with resected 2A who were candidates for consented and enrolled by 105 oncologists from 17...